clinical trial · NCT04179396
Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP)
Metastatic Castration Resistant Prostate CancerRucaparibEnzalutamideAbiraterone
brief summary
Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Oral Rucaparib in Combination with Other Anticancer Agents in Patients with Metastatic Castration Resistant Prostate Cancer
started
Dec 5, 2019
primary completion
Nov 25, 2021
completion
Jan 18, 2023
last updated
Jun 29, 2023
official title
A Phase 1b, Open-label, Parallel Arm Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Oral Rucaparib in Combination With Other Anticancer Agents in Patients With Metastatic Castration Resistant Prostate Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol